title: Are growth factors the answer?
abstract: Growth factors are potentially major players in therapeutic interventions for neurodegenerative disorders like Parkinson's disease (PD) because of their potential to not merely provide symptomatic relief but also be disease modifying agents. Many extensively utilized therapies such as the prodrug levodopa, while unquestionably effective, are intended for symptomatic benefit. Such therapies do little to stifle the progressive nature of these diseases thereby placing temporal restrictions on their effectiveness. Growth factors, by virtue of their distinct neuroprotective properties, have the cumulative effect of curbing disease progression and allaying existing symptoms. The purpose of this review is to discuss some of the growth factors commonly used in animal models of PD and those already used in clinical trials.
authors.affiliation: Department of Neurological Sciences, Rush University Medical Center, Chicago, IL 60612, USA.
authors.forename: Shilpa
authors.initials: S
authors.lastname: Ramaswamy
authors.forename: Jeffrey H
authors.initials: JH
authors.lastname: Kordower
mesh_terms: D000818:Animals; D006801:Humans; D036341:Intercellular Signaling Peptides and Proteins / Q000235:genetics / Q000378:metabolism / Q000627:therapeutic use; D010300:Parkinson Disease / Q000378:metabolism* / Q000628:therapy*
chemical_list: D036341:Intercellular Signaling Peptides and Proteins